The clinical stage biopharmaceutical company Aplagon has just secured a funding round. The company is developing APAC, a pioneering heparin proteoglycan mimetic therapy for thrombo-inflammatory diseases that combines antiplatelet and anticoagulant properties.

The company’s APAC technology functions by replicating the behavior of natural mast cell-derived heparin proteoglycans, targeting areas of arterial damage to deliver sustained antithrombotic and anti-inflammatory effects at the site. The new funding will enable the company to launch a Phase 2a clinical trial investigating APAC’s effectiveness in treating peripheral arterial occlusive disease/chronic limb threatening ischemia (PAOD/CLTI) in Finland. Additionally, the organization has three other clinical trials in progress: a Phase I study examining Arteriovenous Fistula (AVF) maturation failure, a Phase I intravenous (IV) trial with healthy participants, and a PET-imaging study using 89 zirconium-labeled APAC in both PAOD patients and healthy participants, all scheduled for completion in 2025.

The company’s APAC treatment is designed for hospital administration through either local application or intravenous infusion. The therapy has been administered to more than 40 participants thus far, demonstrating a favorable safety profile and promising preliminary clinical results.

The company’s innovative approach, which utilizes a heparin proteoglycan mimetic that can target and remain at vascular injury sites, shows promise for treating various severe vascular conditions. The organization anticipates sharing clinical trial results during 2025 and 2026.